BMS’s strong 2Q outshines mixed Opdivo data in 1L NSCLC

Investors shrugged off mixed data for Opdivo in first-line lung cancer as Bristol-Myers climbed $2.17 to $45.40 on Thursday on 2Q19 earnings that beat the Street's expectations.

Bristol-Myers Squibb Co. (NYSE:BMY) reported postmarket data Wednesday from two separate parts of the Phase III CheckMate -227 trial to treat

Read the full 476 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers